Literature DB >> 19141710

Characterization of the A2B adenosine receptor from mouse, rabbit, and dog.

John A Auchampach1, Laura M Kreckler, Tina C Wan, Jason E Maas, Dharini van der Hoeven, Elizabeth Gizewski, Jayashree Narayanan, Garren E Maas.   

Abstract

We have cloned and pharmacologically characterized the A(2B) adenosine receptor (AR) from the dog, rabbit, and mouse. The full coding regions of the dog and mouse A(2B)AR were obtained by reverse transcriptase-polymerase chain reaction, and the rabbit A(2B)AR cDNA was obtained by screening a rabbit brain cDNA library. It is noteworthy that an additional clone was isolated by library screening that was identical in sequence to the full-length rabbit A(2B)AR, with the exception of a 27-base pair deletion in the region encoding amino acids 103 to 111 (A(2B)AR(103-111)). This 9 amino acid deletion is located in the second intracellular loop at the only known splice junction of the A(2B)AR and seems to result from the use of an additional 5' donor site found in the rabbit and dog but not in the human, rat, or mouse sequences. [(3)H]3-Isobutyl-8-pyrrolidinoxanthine and 8-[4-[((4-cyano-[2,6-(3)H]-phenyl)carbamoylmethyl)oxy]phenyl]-1,3-di(n-propyl)xanthine ([(3)H]MRS 1754) bound with high affinity to membranes prepared from human embryonic kidney (HEK) 293 cells expressing mouse, rabbit, and dog A(2B)ARs. Competition binding studies performed with a panel of agonist (adenosine and 2-amino-3,5-dicyano-4-phenylpyridine analogs) and antagonist ligands identified similar potency orders for the A(2B)AR orthologs, although most xanthine antagonists displayed lower binding affinity for the dog A(2B)AR compared with A(2B)ARs from rabbit and mouse. No specific binding could be detected with membranes prepared from HEK 293 cells expressing the rabbit A(2B)AR(103-111) variant. Furthermore, the variant failed to stimulate adenylyl cyclase or calcium mobilization. We conclude that significant differences in antagonist pharmacology of the A(2B)AR exist between species and that some species express nonfunctional variants of the A(2B)AR due to "leaky" splicing.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19141710      PMCID: PMC2670590          DOI: 10.1124/jpet.108.148270

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

Review 1.  Structure and function of adenosine receptors and their genes.

Authors:  B B Fredholm; G Arslan; L Halldner; B Kull; G Schulte; W Wasserman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-11       Impact factor: 3.000

2.  Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine.

Authors:  J R Pfister; L Belardinelli; G Lee; R T Lum; P Milner; W C Stanley; J Linden; S P Baker; G Schreiner
Journal:  J Med Chem       Date:  1997-06-06       Impact factor: 7.446

3.  cDNA cloning and characterization of A3i, an alternatively spliced rat A3 adenosine receptor variant.

Authors:  F G Sajjadi; D L Boyle; R C Domingo; G S Firestein
Journal:  FEBS Lett       Date:  1996-03-11       Impact factor: 4.124

Review 4.  Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions.

Authors:  J Linden
Journal:  Trends Pharmacol Sci       Date:  1994-08       Impact factor: 14.819

5.  Cardiac effects of adenosine in A(2A) receptor knockout hearts: uncovering A(2B) receptors.

Authors:  R Ray Morrison; M A Hassan Talukder; Catherine Ledent; S Jamal Mustafa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-02       Impact factor: 4.733

6.  A2B adenosine and P2Y2 receptors stimulate mitogen-activated protein kinase in human embryonic kidney-293 cells. cross-talk between cyclic AMP and protein kinase c pathways.

Authors:  Z Gao; T Chen; M J Weber; J Linden
Journal:  J Biol Chem       Date:  1999-02-26       Impact factor: 5.157

7.  Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor.

Authors:  Q Y Zhou; C Li; M E Olah; R A Johnson; G L Stiles; O Civelli
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist.

Authors:  S M Poucher; J R Keddie; P Singh; S M Stoggall; P W Caulkett; G Jones; M G Coll
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

9.  The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist.

Authors:  Veli-Pekka Jaakola; Mark T Griffith; Michael A Hanson; Vadim Cherezov; Ellen Y T Chien; J Robert Lane; Adriaan P Ijzerman; Raymond C Stevens
Journal:  Science       Date:  2008-10-02       Impact factor: 47.728

10.  Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors.

Authors:  D Ukena; K A Jacobson; W L Padgett; C Ayala; M T Shamim; K L Kirk; R O Olsson; J W Daly
Journal:  FEBS Lett       Date:  1986-12-01       Impact factor: 4.124

View more
  18 in total

1.  Transgenic over expression of ectonucleotide triphosphate diphosphohydrolase-1 protects against murine myocardial ischemic injury.

Authors:  Ming Cai; Zachary M Huttinger; Heng He; Weizhi Zhang; Feng Li; Lauren A Goodman; Debra G Wheeler; Lawrence J Druhan; Jay L Zweier; Karen M Dwyer; Guanglong He; Anthony J F d'Apice; Simon C Robson; Peter J Cowan; Richard J Gumina
Journal:  J Mol Cell Cardiol       Date:  2011-09-12       Impact factor: 5.000

Review 2.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

3.  Differential effects of adenosine A2a and A2b receptors on cardiac contractility.

Authors:  P Charukeshi Chandrasekera; Victoria J McIntosh; Frank X Cao; Robert D Lasley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-10-08       Impact factor: 4.733

Review 4.  Recent developments in adenosine receptor ligands and their potential as novel drugs.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Biochim Biophys Acta       Date:  2010-12-23

5.  Ectonucleotide triphosphate diphosphohydrolase-1 (CD39) mediates resistance to occlusive arterial thrombus formation after vascular injury in mice.

Authors:  Zachary M Huttinger; Michael W Milks; Michael S Nickoli; William L Aurand; Lawrence C Long; Debra G Wheeler; Karen M Dwyer; Anthony J F d'Apice; Simon C Robson; Peter J Cowan; Richard J Gumina
Journal:  Am J Pathol       Date:  2012-05-18       Impact factor: 4.307

Review 6.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

7.  Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors.

Authors:  Mohamad Wessam Alnouri; Stephan Jepards; Alessandro Casari; Anke C Schiedel; Sonja Hinz; Christa E Müller
Journal:  Purinergic Signal       Date:  2015-07-01       Impact factor: 3.765

8.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

9.  Characterization of Dahl salt-sensitive rats with genetic disruption of the A2B adenosine receptor gene: implications for A2B adenosine receptor signaling during hypertension.

Authors:  Shraddha Nayak; Md Abdul H Khan; Tina C Wan; Hong Pei; Joel Linden; Melinda R Dwinell; Aron M Geurts; John D Imig; John A Auchampach
Journal:  Purinergic Signal       Date:  2015-09-18       Impact factor: 3.765

10.  Contribution of adenosine A(2B) receptors in Clostridium difficile intoxication and infection.

Authors:  Cirle A Warren; Yuesheng Li; Gina M Calabrese; Rosemayre S Freire; Snjezana Zaja-Milatovic; Edward van Opstal; Robert A Figler; Joel Linden; Richard L Guerrant
Journal:  Infect Immun       Date:  2012-10-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.